의료진 소개
예약 안내
박지현
[
종양혈액내과
]
두경부암, 식도암, 폐암, 비뇨생식기암, 대장직장암, 육종, 흑색종, 임상연구클리닉
고맙습니다
예약문의
1588-1533
1588-1533
외래진료 외래진료
특수클리닉 특수클리닉
진료일정
10
| 날짜 |
|---|
| 오전 |
| 오후 |
논문
논문
- Park JH. Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers. BMC Medicine. 2024 Sep 27;22:422.
- Park JH. Phase III, Randomized study of Atezolizumab plus Bevacizumab and Chemotherapy in Patients with EGFR- or ALK-Mutated in Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). Journal of Clinical Oncology. 2024 Apr 10;42(11):1241-51.
- Park JH. Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study. Anticancer Research. 2024 Jan;44(1):347-59.
- Park JH. A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21). Journal of Thoracic Oncology. 2023 Feb;18(2):223-31.
- Park JH, Lee SH, Cho KR, Cho J, Koh YC, Choi JW, Lim SD, Koh HG, Yoon SY. Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors. Anticancer Research. 2022 Dec;42(12):6091-8.
- Park JH. Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with that of Orthogonal Methods for Detecting Targetable Genetic Alterations. Cancer Research and Treatment. 2022 Jan;54(1):30-9.
- Park JH. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Journal of Cancer Research and Clinical Oncology. 2021 Aug;147(8):2459-69.
- Park JH. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. Cancer Research and Treatment. 2021 Jul;53(3):671-7.
- Park JH. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12. Journal of Cancer Research and Clinical Oncology. 2020 Dec;146(12):3359-69.
- Park JH. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. Anticancer Research. 2020 Oct;40(10):5883-93.
- Park JH. How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers. Journal of Cancer Education. 2020 Jun;35(3):545-56.
- Park JH, Jonas SF, Bataillon G, Criscitiello C [et al.]. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Annals of Oncology. 2019 Dec;30(12):1941-1949.
- Lee HS, Lee JW, Park JH, Kim WS, Han HS, Lee SE. Comprehensive analysis for diagnosis of preoperative non-invasive follicular thyroid neoplasm with papillary-like nuclear features. PLoS One. 2019 Jul 5;14(7):e0218046.
- Park JH, Kwon BS, Park SJ, Ji W, Yoon S, Choi CM, Lee JC. Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 2019 Jul;145(7):1897-1905.
- Park JH, Lee HJ, Lee SB, Ahn JH, Kim JE, Jung KH, Gong G, Son BH, Ahn SH, Kim SB. Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer. Anticancer Research. 2019 Jun;39(6):3111-3119.
- Kwon BS, Park JH, Kim S, Park S, Ji W, Kim WS, Lee JC, Park YR, Choi CM. Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer. Tumori. 2019 Jun;105(3):216-224.
- Park JH. . Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis. . Oncotarget. . 2017 Aug 8;8(32):53326-35. .
- JH Park, DH Yoon, S.Kim, JS Park, C-S Park, H. Sung, S-W Lee, J.Huh, C Suh. Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphoma (MZL) . Hematological Oncology. (2017), Apr 11, doi:10.1002/hon 2414 .
- BS Kwon, JH Park, WS Kim, JS Song, CM Choi, JK Rho, JC Lee . Predictive factors for switched EGFR-TKIs retreatment in patients with EGFR-mutant Non-small cell lung cancer . Tuberculosis and Respiratory Disease. (2017), Apr; 80(2): 187-193 .
- S. Seo, JY Hong, S. Yoon, C. Yoo, JH Park, JB Lee, C-S Park, J. Huh, Y. Lee, KW Kim, J-S Ryu, SJ Kim, WS Kim, DH Yoon, C. Suh . Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era . Oncotarget. (2016), October, doi: 10.18632/oncotarget.12734 .
- JH Park, MJ Kang, JH Ahn, JE Kim, KH Jung, G. Gong, HJ Lee, B-H Son, S-H Ahn, H-H Lee, HJ Shin, D-H Moon, S-B Kim . Phase II Trial of Neoadjuvant Letrozole and Lapatinib in Asian Postmenopausal Women With Estrogen Receptor (ER) and Human Epidermal Growth Factor Receptor-2 (HER-2) Positive Breast Cancer [Neo-ALL-IN]: Highlighting the TILs, ER Expressional Change after Neoadjuvant Treatment, and FES-PET as Potential Significant Biomarkers. Cancer Chemotherapy and Pharmacology. (2016), August, 78:685, doi: 10.1007/s00280-016-3107-6 .
- JH Park, YJ Choi, SY Kim, J-E Lee, KJ Sung, S.Park, WS Kim, JS Song, C-M Choi. YH Sung, JK Rho. JC Lee . Activation of IGF1R Pathway Potentially Mediates Acquired Resistance to Mutant-selective 3rd-generation EGF Receptor Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer . Oncotarget. (2016), March, doi: 10.18632/oncotarget.8013 .
- JH Park, DH Yoon, S.Kim, JS Park, C-S Park, H. Sung, S-W Lee, J.Huh, C Suh . Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma . Annals of Hematology. (2016), April, 95: 801-808, doi: 10.1007/s00277-016-2610-5 .
- JH Park, M-H Ryu, HJ Kim, B-Y Ryoo, C. Yoo, I. Park, YS Park, ST Oh, JH Yook, BS Kim, Y-K Kang . Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer, . Gastric Cancer. (2016) Jan; 19 (1): 226-33, doi 10.1007/s10120-015-0464-5 .
- JH Park, M-H Ryu, YS Park, SR Park, Y-S Na, B-Y Rhoo, Y-K Kang (2015) . Successful control of heavily pretreated metastatic gastric cancer with the mTOR Inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression. . BMC Cancer. (2015) Mar 13;15:119, doi 10.1186/s12885-015-1139-7 .
- JH Park, J-L Lee . Intravenous 3-Weekly Paclitaxel and Metronomic Oral Cyclophosphamide in Patients with Advanced Urothelial Cancer Previously Treated with Gemcitabine and Platinum, . Cancer Chemotherapy and Pharmacology. (2015): 75 (2), 247-254, doi: 10.1007/s00280-014-2640-4. .
- JH Park, DH Yoon, SM Kim, S.Kim, S-W Lee, C-S Park, J.Huh, C Suh . The highest prognostic impact of LDH among International Prognostic Indices (IPI): An explorative study of five IPI factors among patients with DLBCL in the era of Rituximab, . Annals of Hematology. (2014), 93 (10), 1755-1764, doi: 10.1007/s00277-014-2115-z .
- Kang, Y. K., Yoo, C., Ryoo, B. Y., Lee, J. J., Tan, E., Park JH, Park, I., et al. . Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. . British Journal of Cancer. (2013), 109(9), 2309–2315. doi:10.1038/bjc.2013.594 .
- C Yoo, JH Park (Co-first author), DH Yoon, SI Park, HR Kim, JH Kim, HY Jung, GH Lee, KD Choi, HJ Song, HY Song, JH Shin, KJ Cho, YH Kim, SB Kim . Salvage Esophagectomy for Locoregional Failure After Chemoradiotherapy in Patients with advanced Esophageal Cancer . Annals of Thoracic Surgery. 2012;94(6);1862-1868.